The Australian Pesticides and Veterinary Medicines Authority (APVMA) is considering an application for approval of the new active constituents Leptospira interrogans serogroup Canicola serovar Canicola strain 16070 (Canicola) and Inactivated Leptospira interrogans serogroup and serovar Grippotyphosa strain Grippo Mal 1540 (Grippotyphosa) and registration of the product Protech Lepto 4 Inactivated Vaccine for Dogs, containing 130 Formazine Turbidity Units (FTU) of Canicola and 340 FTU of Grippotyphosa.
We invite relevant written comment from 19 May to 16 June 2026 on whether approval of the active constituents and registration of the product should be granted.
The APVMA is able to consider comments relating to the legislative grounds, including:
- chemistry and manufacture
- human health
- environmental safety
- efficacy and Target animal safety.
For more information see page 14 to 27, in the APVMA Gazette No 10, Tuesday 19 May 2026.
Please lodge your submission with a public submission coversheet. The coversheet provides options for how your submission will be published.
Please note that submissions will be published on the APVMA’s website unless you have asked for the submission to remain confidential. Note that all APVMA documents are subject to the access provisions of the Freedom of Information Act 1982 and may be required to be released under that Act should a request for access be made.
Please send your written submission by email or post to:
Case Management
Australian Pesticides and Veterinary Medicines Authority
GPO Box 574
Canberra ACT 2601, Australia
Email: casemanagement@apvma.gov.au